摘要
脑缺血再灌注损伤(cerebral ischemia-reperfusion injury, CIRI)是全球高发疾病,尽管救治技术有了较大进展,但相当部分CIRI患者仍面临死亡与神经功能障碍等不良预后结局,给社会和家庭造成极大负担。近年来有研究发现,间充质干细胞(mesenchymal stem cells, MSCs)在减轻缺血再灌注后脑损伤、促进内源性修复等方面显示出优于传统干预方式的疗效。本文就MSCs在CIRI治疗中的应用现状及作用机制做一综述。
Cerebral ischemia-reperfusion injury(CIRI) is a high incidence of disease with high mortality and disability in the world. Despite the great efforts of the medical community, a considerable number of CIRI patients still face poor-outcomes including the death and neurological dysfunction, which causes a great economic burden to the society and families. Recent studies shows that mesenchymal stem cells(MSCs) have better therapeutic effects in reducing brain injury and promoting endogenous repair after ischemia-reperfusion compared with the traditional interventions. This article reviews the current status and mechanisms of MSCs in the treatment of CIRI.
作者
葛风
徐杰丰
张茂
Ge Feng;Xu Jie-feng;Zhang Mao(Emergency Medicine Department of the Second Affiliated Hospital of Zhejiang University Medical College,Zhejiang Key Laboratory of Severe Trauma and Burn Diagnosis and Treatment,Zhejiang Research Center for Clinical Medicine of Acute and Critical Illness,Hangzhou 310009,China)
出处
《中国急救医学》
CAS
CSCD
2023年第3期234-238,共5页
Chinese Journal of Critical Care Medicine
基金
国家自然科学基金(82072126)
浙江省重点研发计划项目(2021C03073、2021C03036)。
作者简介
葛风(1990-),女,硕士,主治医师,E-mail:1241882923@qq.com;通信作者:张茂(1974-),男,博士,主任医师,教授,E-mail:z2jzk@zju.edu.cn。
